Dupixent vs Skyrizi
Side-by-side cost comparison based on Medicare Part D data
Dupixent
Dupilumab
Manufactured by Regeneron/Sanofi
Skyrizi
Risankizumab
Manufactured by AbbVie
Dupixent costs 37% less per claim than Skyrizi ($2,819.00 vs $4,475.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Dupixent | Skyrizi |
|---|---|---|
| Avg Cost Per Claim | $2,819.00 | $4,475.00 |
| Total Medicare Spending | $4.4B | $2.3B |
| Total Beneficiaries | 245,000 | 78,000 |
| Total Claims | 1,560,000 | 524,000 |
| Annual Cost/Patient | $17,951.00 | $30,064.00 |
| Year-over-Year Change | +35.2% | +42.8% |
| Generic Available | No | No |
| Patent Expiration | Mar 28, 2031 | Apr 23, 2035 |
| Manufacturer | Regeneron/Sanofi | AbbVie |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Dupilumab | Risankizumab |
Dupixent vs Skyrizi: What the Data Shows
Dupixent (Dupilumab) and Skyrizi (Risankizumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Dupixent costs $2,819.00 per claim, which is 37% less than Skyrizi at $4,475.00 per claim.
Medicare spent $4.4B on Dupixent and $2.3B on Skyrizi. In terms of patient reach, Dupixent serves more beneficiaries (245,000 vs 78,000).
Year-over-year spending changed +35.2% for Dupixent and +42.8% for Skyrizi. Dupixent saw significant spending growth, suggesting increased utilization or price increases. Skyrizi saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Dupixent patent expires Mar 28, 2031. Skyrizi patent expires Apr 23, 2035.
Frequently Asked Questions
Dupixent is cheaper at $2,819.00 per claim, compared to $4,475.00 for Skyrizi. That makes Dupixent about 37% less expensive per claim based on Medicare Part D data.
Yes, both Dupixent and Skyrizi are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Dupixent patent expires Mar 28, 2031. Skyrizi patent expires Apr 23, 2035.
Medicare Part D spent $4.4B on Dupixent covering 245,000 beneficiaries, and $2.3B on Skyrizi covering 78,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.